Eli Lilly and Sosei enter into diabetes and metabolic disease deal, going after GPCR
Japan’s Sosei Heptares is partnering up with another big-name player: Eli Lilly.
Under the agreement, Eli Lilly will pay Sosei $37 million upfront with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
